NewAmsterdam Pharma Co N.V (NAMS) Insider & Congress Trades

Smart money at a glance

Filings to Nov 14, 2026

Net selling: insiders sold $4.7M and bought $227K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$4.4M net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about NAMS filings

Are insiders buying or selling NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) stock?

Net selling: insiders sold $4.7M and bought $227K of NAMS stock on the open market in the 90 days to Nov 14, 2026, according to SEC Form 4 filings. $4.6M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Kastelein, Johannes Jacob Pieter (Chief Scientific Officer), who sold $4.6M. The latest filing was on Oct 2, 2026.

Which members of Congress have traded NAMS recently?

None. No member of Congress disclosed a NAMS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this NAMS smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Filings could not be loaded.

26 funds hold a position and insiders have been net selling.

Questions about NAMS filings

Are insiders buying or selling NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) stock?

Which members of Congress have traded NAMS recently?

None. No member of Congress disclosed a NAMS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this NAMS smart-money data?

Funds

What funds are doing

1 move · 6 mo

Buys/Adds$25.0M

Buys/Adds (1)

SU
Susquehanna
Q2 2026 13F
$25.0M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 4, 2026

Earnings came in 71.4% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 4, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.12+71.37% beat

-$0.44 expected

Revenue

$19.2M

SEC filing

EPS: Yahoo Finance

Next report

What the street expects next

Estimates as of Nov 10, 2026

EPS expected

-$0.40

-$0.58 to -$0.24

Revenue expected

$18.2M

10 analysts

Last 30 days

2up4down

Analysts cutting estimates

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 4, 2026	-$0.12est. -$0.44	+71.37%beat	$19.2MSEC filing	+5406.9%from $348.0K
Jun 30, 2026Reported Aug 5, 2026	-$0.45est. -$0.43	-5.70%miss	$3.7MSEC filing	-80.7%from $19.1M
Mar 31, 2026Reported May 7, 2026	-$0.34est. -$0.41	+16.50%beat	$3.0MSEC filing	+2.1%from $3.0M
Dec 31, 2025Reported Feb 18, 2026	-$0.53est. -$0.37	-45.31%miss	$27.1KYahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 5, 2025	-$0.41est. -$0.38	-7.89%miss	$348.0KSEC filing	-98.8%from $29.1M
Jun 30, 2025Reported Aug 6, 2025	-$0.13est. -$0.43	+69.77%beat	$19.1MSEC filing	+740.1%from $2.3M
Mar 31, 2025Reported May 8, 2025	-$0.30est. -$0.44	+31.82%beat	$3.0MSEC filing	+112.6%from $1.4M
Dec 31, 2024Reported Feb 26, 2025	-$0.93est. -$0.96	+3.13%beat	$45.6M · FYSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $20.76
High: $20.76
Low: $19.31
Prev close: $20.72
52-wk high: $42.20
52-wk low: $17.90
Mkt cap: $2.48B
ROE: -30.2%
Fwd P/E: 101.0x
Beta: 0.14
P/S: 95.8x
P/B: 3.6x
Profit margin: +0.0%
Op margin: -900.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Forward P/E: 101.01
Market cap: $2.5B

Valuation

P/S95.81
P/B3.65

Quality

Operating margin-900.0%
ROE-30.2%
ROA-19.8%

Growth

Beta0.14

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

15 / 100

RSI 14

51balanced

20D volatility

72%annualized

52-week range

$19.97

$17.90$42.20

20D support

$17.90recent floor

20D resistance

$22.29recent ceiling

Returns

5D +5.7%20D -3.2%60D -30.0%

Price vs moving averages

SMA20 -1.0%SMA50 -7.7%SMA200 -31.6%

Volume pace

1.04xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 4, 2026

-$0.12est. -$0.44

+71.37%

$19.2MSEC filing

+5406.9%from $348.0K

Jun 30, 2026Aug 5, 2026

-$0.45est. -$0.43

-5.70%

$3.7MSEC filing

-80.7%from $19.1M

Mar 31, 2026May 7, 2026

-$0.34est. -$0.41

+16.50%

$3.0MSEC filing

+2.1%from $3.0M

Dec 31, 2025Feb 18, 2026

-$0.53est. -$0.37

-45.31%

$27.1KYahoo Finance

No year-ago quarter

Sep 30, 2025Nov 5, 2025

-$0.41est. -$0.38

-7.89%

$348.0KSEC filing

-98.8%from $29.1M

Jun 30, 2025Aug 6, 2025

-$0.13est. -$0.43

+69.77%

$19.1MSEC filing

+740.1%from $2.3M

Mar 31, 2025May 8, 2025

-$0.30est. -$0.44

+31.82%

$3.0MSEC filing

+112.6%from $1.4M

Dec 31, 2024Feb 26, 2025

-$0.93est. -$0.96

+3.13%

$45.6M · FYSEC filing

No year-ago quarter

NewAmsterdam Pharma Company N.V. Ordinary Shares

Smart money at a glance

What do analysts expect?

Questions about NAMS filings

Questions about NAMS filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 71.4% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

NewAmsterdam Pharma Company N.V. Ordinary Shares

Smart money at a glance

What do analysts expect?

Questions about NAMS filings

Questions about NAMS filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 71.4% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

NewAmsterdam Pharma Company N.V. Ordinary Shares

Overview

Questions about NAMS filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

NewAmsterdam Pharma Company N.V. Ordinary Shares

Overview

Questions about NAMS filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.